

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 3, 2026

**TURN THERAPEUTICS INC.**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation)

**001-42875**  
(Commission File Number)

**32-0456090**  
(IRS Employer  
Identification Number)

**250 N. Westlake Blvd., Westlake Village, California**  
(Address of principal executive offices)

**91362**  
(Zip Code)

Registrant's telephone number, including area code: **(818) 564-4011**

N/A  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Common Stock, par value \$0.0001 per share	TTRX	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01 Regulation FD Disclosure.**

On June 1, 2026, Turn Therapeutics Inc. released an updated investor presentation (the “Investor Presentation”). A copy of the Investor Presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K and the Investor Presentation furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits**

<b>Exhibit No.</b>	<b>Description</b>
99.1	<a href="#">Investor Presentation, dated June 3, 2026</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**TURN THERAPEUTICS INC.**

Date: June 3, 2026

By: /s/ Bradley Burnam  
Name: Bradley Burnam  
Title: Chief Executive Officer

ADVANCING NON-SYSTEMIC MEDICINES FOR  
INFLAMMATORY SKIN DISEASES



**TURN**  
THERAPEUTICS

June 2026

**2026 Jefferies Global Healthcare  
Conference**



# Disclaimer

Except for historical information set forth herein, the matters set forth in this presentation contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue," the negative of these terms and other comparable terminology. We cannot guarantee future results, level of activity, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. We are under no duty to update any of these forward-looking statements after the date of this presentation to conform our prior statements to actual results or revised expectations.

These statements are based upon the current beliefs and expectations of Turn Therapeutics' management and are subject to significant risks and uncertainties. By their nature, forward-looking statements involve risks and uncertainties because they depend on circumstances that may or may not occur in the future. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially.


Risks include: industry competition; economic factors; regulatory challenges; uncertainties in clinical development and obtaining regulatory approvals; no guarantees that pipeline products will prove commercially successful; reliance on third-party partnerships and manufacturers; dependence on patent protections for PermaFusion®; and ability to access adequate capital.

Although these statements are based on assumptions we believe are reasonable, we caution that forward-looking statements are not guarantees of future performance and you should not place undue reliance on them. Turn Therapeutics undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors can be found in the company's SEC filings available at [www.sec.gov](http://www.sec.gov).

This presentation includes market and industry data and forecasts that the Company has derived from independent consultant reports, publicly available information, various industry publications, other published industry sources, and its internal data and estimates. Independent consultant reports, industry publications and other published industry sources generally indicate that the information contained therein was obtained from sources believed to be reliable. Although the Company believes that these third-party sources are reliable, it does not guarantee the accuracy or completeness of this information, and the Company has not independently verified this information. The Company's internal data and estimates are based upon information obtained from trade and business organizations and other contacts in the markets in which the Company operates and management's understanding of industry conditions. Although the Company believes that such information is reliable, it has not had this information verified by any independent sources. In addition, the information contained in this presentation is as of the date hereof (except where otherwise indicated), and the Company has no obligation to update such information, including in the event that such information becomes inaccurate or if estimates change. Subsequent materials may be provided by or on behalf of the Company in its discretion and such information may supplement, modify or supersede the information in these materials. Neither the Company, nor any of its respective affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss or damage howsoever arising from any use of these materials or their contents or otherwise arising in connection with these materials.

This presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this presentation may be listed without the TM, SM or symbols, but the Company will assert, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, service marks, trade names and copyrights.

# PermaFusion: API Agnostic Delivery Platform



A transformative delivery platform enabling stable, emulsifier-free dispersion of active ingredients in oil-based carriers for superior penetration by APIs

- Multi-patented, proprietary process
- API-agnostic drug delivery platform designed for continued innovation
- Suspended, non-diluted nanodroplets embedded within oil-based carrier deliver active ingredients through skin, nails, and mucous membranes
- Compatible with any liquid or liquid-soluble API, including live payloads (i.e. viruses/vectors)

## — Executive Summary

Turn Therapeutics is a biotechnology company developing first-in-class, precision, non-systemic immunomodulation therapies that target IL-36 and key downstream cytokines to address high-unmet-need inflammatory diseases, with an initial focus on moderate to severe AD.

### IL-36/IL-31 Inhibitor – GX-03

#### Novel MOA

employs precision immunomodulation to prevent unnecessary immune activation and systemic uptake

**200,000+**

patients have received GX-03<sup>1</sup>

**ZERO**

reported adverse events

#### Robust IP

including issued composition and method patents, supporting durable commercial exclusivity

#### Phase 2 RCT trial

underway for moderate to severe AD, topline results expected mid-2026

#### FDA clearances

with non-cytotoxic, non-sensitizing and non-irritating claims




1. In other FDA cleared indications (or as a management tool for chronic wound care)

# Turn Tx Pipeline

## GX-03

IL-36, IL-36, IL-31 and IL-4 inhibitor

Non-systemic and non-steroid potentially best-in-class topical



## Medical Devices




FDA-cleared antimicrobial surgical gauze out-licensed



Sterile collagen powder out-licensed for \$70M+ milestones

**GX-03 for AD**




# The Chronic Inflammatory 'Loop'

## Skin Barrier Disruption

Skin barrier disruption results in release of IL-36

## IL-31 Drives Itch & Scratch

IL-31 release drives itch which leads to further disruption of the skin barrier and restarts loop



## Th2 Immune Response

IL-36 initiates TH2 signaling with IL-4, IL-13, and IL-31 release


# Chronic AD Cycle

# Stop the 'Loop'

## IL-36 and IL-31 Inhibition

GX-03 targets key upstream and downstream cytokines to stop the chronic inflammatory 'loop'


**GX-03 suppresses IL-31** signaling, blunting itch/scratch signal and continued barrier disruption



**GX-03 suppresses IL-36** release via targeted modulation of the epithelial microenvironment, blunting Th2 response

## GX-03 Inhibition

## Phase 2 Adaptive Study Design



### Initial Trial Design – Stage 1

#### Population:

- Moderate-Severe Atopic Dermatitis based on EASI (>7) or IGA of 3/4
- Age: 18 – 80
- N = 120 – 200 (adaptive)

#### Design:

- Double-blind
- 1:1 Randomized
- Vehicle Controlled
- Week 4 and Week 8 Endpoints
- IDMC Governed Adaptive Design

#### Endpoints & Exploratory Measurements:

- vIGA 0 or 1 and  $\geq 2$  points drop at W4 & W8
- % change in EASI at W4 & W8
- PP-NRS (itch)  $\geq 4$  points drop at W4 & W8
- Patient Oriented Eczema Measure (POEM) at W4 & W8

## — Interim Analysis Population - Baseline Characteristics

	FAS N = 50	GX-03 N = 27	Vehicle N = 23
<b>Baseline EASI</b>			
Mean	8.19	10.16	5.87
Range	1.2 - 43.1	1.2 - 43.1	1.4 - 19.5
Standard Deviation	8.85	10.93	4.77
Baseline EASI ≥ 21, n (%age)	4 (8%)	4 (15%)	0 (0%)
<b>Baseline IGA [0-4 score]</b>			
Mean	3.12	3.19	3.04
Range	2 - 4	3 - 4	2 - 4
Standard Deviation	0.39	0.40	0.37
Baseline IGA = 4, n (%age)	7 (14%)	5 (19%)	2 (9%)
<b>PP-NRS (itch) [0-10 score]</b>			
Mean	6.36	6.07	6.7
Range	0 - 10	0 - 10	3 - 10
Standard Deviation	2.37	2.60	2.08
Baseline ≥ 6, n (%age)	35 (70%)	18 (67%)	17 (74%)


## Interim Analysis – Summary Results of Stage 1 Endpoints and Commonly Tracked AD Measurements

	Week 4			Week 8		
	GX-03 At Week 4	Vehicle At Week 4	Difference	GX-03 At Week 8	Vehicle At Week 8	Difference
Change EASI Mean % Reduction	79.43%	50.55%	28.88%	77.22%	62.70%	14.52%
EASI-50 (%pts)	92.6%	65.2%	27.39%	81.5%	69.6%	11.93%
EASI-75 (%pts)	70.4%	56.5%	13.85%	66.7%	56.5%	10.20%
EASI-90 (%pts)	44.4%	30.4%	14.01%	51.9%	34.8%	17.12%
EASI-100 (%pts)	18.5%	4.3%	14.15%	40.7%	17.4%	23.31%
IGA 0 or 1 (% pts)	59.3%	34.8%	24.50%	70.4%	65.2%	5.20%
PP-NRS 0 or 1 (% pts)	55.6%	39.1%	16.43%	63.0%	60.9%	2.09%


Week 4

Week 8






## Interim Analysis - EASI Percentage Reduction Over Time



## Interim Analysis - EASI Responder Rates



# Select Patients With High Baseline Disease Burden






## — Interim Analysis - Safety Summary

	<b>GX-03</b> N = 27	<b>Vehicle</b> N = 23	
Subjects with AE, n	1*	1**	<i>*Subject reported a mild warming sensation that was described as pleasant.</i> <i>**Subject reported a common cold which was determined by PI to be unrelated to study.</i>
Severe (Grade ≥ 2)	0	0	
Serious AEs	0	0	
AEs leading to study drug discontinuation	0	0	

“Favorable safety and tolerability profile is encouraging and supports the potential for GX-03 to become an important **first-line treatment option**”

*Dr. Stephen Bresnick, MD*

# — GX-03 Interim Analysis Findings Compared to Pivotal Trials for Approved Topicals\*\*



\* Product approved for mild-to-moderate Atopic Dermatitis

\*\* For illustrative purposes only: Not a head-to-head analysis. Comparisons of data should be interpreted with caution due to differences in compounds, study designs, subject characteristics, and other factors that may limit direct comparability.

## — Trial Optimization Strategy – Stage 2

### **Endpoint Strategy:**

Interim findings suggest GX-03 activity may be most visible and clinically meaningful in earlier efficacy measures evaluating reduction in inflammatory burden. Based on these observations and advisor feedback, Stage 2 is expected to emphasize Week 4 endpoints, with EASI-75 emerging as a leading candidate due to its clinical relevance, regulatory precedent, and alignment with the observed product profile.

### **Anticipated Inclusion Criteria:**

Baseline EASI of  $\geq 7$ , BSA of  $\geq 8\%$ , IGA of 3 or 4 and PP-NRS  $\geq 4$ .

### **Enrollment Status:**

Ongoing enrollment nearing N=100. Sample size adaptation TBD pending consultation with IDMC.

### **Type B Meeting Package in Progress:**

Preparation of a Type B meeting package is underway. Discussions are expected to focus on opportunities to optimize the GX-03 development pathway, leveraging the formula's continuing favorable safety profile and observed rapid onset of activity.

## — GX-03 - Commercial Opportunity



*Potential for Safe, Rapid Disease Control Without Systemic Exposure*

## Phase 3 Ready

GX-03 for Onychomycosis

## Phase 2 Equivalent Study

### Study Design

- N ~ 100
- GX-03 applied once daily or BID application
- No debridement or occlusive dressings required

### Study Results

- Visible evidence of Beau's line development, **clear nail plate**
- **70% efficacy** (approx.) with once-daily application
- **85% efficacy** (approx.) with BID application
- **No adverse events** reported during the study




## “Novel Approach to Polymicrobial Nail Infection”

*R. Dan Davis, DPM*


## Current Topicals for Onychomycosis

Currently approved topical onychomycosis products have **failed to penetrate the nail** and eliminate fungal pathogens leading to lower efficacy:



In the same in-vivo model, GX-03 successfully penetrated the nail, **REDUCING FUNGAL BURDEN BY 12% - 18%** with just two weeks of application.<sup>1</sup>

Lipid-based delivery enables passive diffusion of API through lipid bilayers.



**GX-03 successfully penetrated nails and eliminated fungal pathogens in the standard model**

# Onychomycosis TAM & Prevalence

**Only 15%**

of the affected population seeks treatment due to lack of awareness, limited efficacy and hepatotoxicity of available therapeutics


**47.6M**

patients suffer from onychomycosis in U.S.

**1 in 7**

people globally suffers from onychomycosis<sup>1</sup>

## US Market Size<sup>2</sup>



## High Unmet Needs

- Effective therapies as current topical treatments are only 6-18% effective
- Patent cliff for current onychomycosis treatments in 2026

## GX-03 Path to Market<sup>3</sup>




1. [www.cdc.gov](http://www.cdc.gov)

2. [Precedence Research - Onycho Treatment market.com](https://precedence-research.com/OnychoTreatmentMarket)

3. Subject to successful completion of each phase and capital availability.

## Our Science



## GX-03 Broader Opportunities in Dermatology and I&I Diseases

### IL-36

Hidradenitis Suppurativa

Auto-immune Blistering Diseases

Psoriasis

Actinic Keratosis

### IL-31

Prurigo Nodularis

Bullous Pemphigoid

Chronic Pruritus

## Corporate & Financial Highlights

## Financial & IP Highlights

**~\$250K/mo.**

Expected G&A burn as a public co.

**\$29M**

Total money raised since inception (2015)

**\$18M**

Cash burned since inception

**\$55-60M**

Expected R&D spend for Phase 3 trials on both indications

**\$10-13M**

Expected G&A spend to thru 2028

**\$11M Cash Balances**

As of March 31, 2026

**Cash Runway into Q1'2027**

Additional debt/equity tranches available under existing facilities

**~30M Common Shares Outstanding**

As of March 31, 2026

**Extensive Patent Families**

Various patent families for composition and/or methods around API

**17 Issued Patents**

Various additional applications pending

**Coverage Through 2037**

Various applications pending to extend coverage

# Management & Board

## Board Members



**Arthur Golden, JD**  
Senior Counsel, Davis  
Polk & Wardwell



**Andrew Gengos**  
Former CFO Terns  
Pharmaceuticals



**Kent Kester, MD**  
Executive Director,  
Vaccine Research and  
Development at CEPI



**Martin Dewhurst**  
McKinsey Veteran  
Senior Advisor at PJT  
Partners

Arthur Golden, JD

## Key Management



**Bradley Burnam**  
CEO,  
Chairman & Founder



**Dr. Neil  
Ghodadra, MD**  
Chief Medical Officer



**Dr. Stephen  
Hahn, MD**  
Clinical and  
Regulatory Lead



**Sasha  
Damouni Ellis**  
Corporate  
Communications & IR



**Zuraiz  
Chaudhary**  
Chief Accounting Officer



## Advisors & KOLs



**Dr. Robert Redfield**  
Former Director, CDC

Dr. Redfield is a nationally recognized virologist and public health leader who served as Director of the CDC. As Senior Advisor of Health Policy and Regulatory Affairs at Turn.



**Dr. R. Daniel Davis, DPM**  
Former President, CPMA & APMA Board of Trustee

Dr. Davis is board Certified Foot and Ankle Surgeon and has been in practice for over 30 years. Dr. Dan Davis is an advisor and KOL for Turn's onychomycosis program.



**Stephen Bresnick, MD**  
Board Certified Plastic Surgeon

Dr. Stephen Bresnick is a board-certified surgeon in skin health and immunology-related fields, has two doctorate degrees, and is an esteemed research publisher. Dr. Bresnick is an advisor and KOL for Turn's Atopic Dermatitis program.

ADVANCING NON-SYSTEMIC MEDICINES FOR  
INFLAMMATORY SKIN DISEASES



**T U R N**  
T H E R A P E U T I C S

[Investors@turntherapeutics.com](mailto:Investors@turntherapeutics.com)

250 N. Westlake Blvd, #210  
Westlake Village, CA 91362

**Thank You.**

